MedPath

Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids

Recruiting
Conditions
Uterine Fibroid
Interventions
Device: Body System - Functional
Registration Number
NCT05386615
Lead Sponsor
InSightec
Brief Summary

The goal of this Registry Study is to capture clinical pregnancy outcomes and fibroid treatment background data for any subject post-Exablate treatment for their symptomatic fibroids.

Detailed Description

This is an observational study only for all consented subjects who undergo an Exablate treatment. The Exablate procedure is a commercial treatment. The objective of this registry is to collect data about the effect of Exablate treatment on potential pregnancy occurrences in this population for two years post-treatment for purposes of labeling updates and overall safety data collection.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
200
Inclusion Criteria
    • Eligibility is as per the symptomatic fibroids device indication. - All registry-consented patients following the treatment of their fibroid(s) with the Exablate system.
Exclusion Criteria

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
ExablateBody System - FunctionalObservational study of Exablate treatment.
Primary Outcome Measures
NameTimeMethod
Occurrence of adverse eventsThrough study completion, an average of 2 years.

All adverse events and/or serious adverse events will be documented and reported according to protocol.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (6)

Shanghai No. 1 Hospital

🇨🇳

Shanghai, China

UCLA

🇺🇸

Los Angeles, California, United States

Stanford University

🇺🇸

Stanford, California, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

Huashan Hospital Affiliated to Fudan University

🇨🇳

Shanghai, China

Shanghai No.1 Hospital

🇨🇳

Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath